All In Biotech

Drug Trial Radar · NCT05585606

Study of the Safety and Neuroprotective Capacity of Scp776 in Acute Ischemic Stroke

A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke

Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

120

Actual

Start

Oct 19, 2022

Primary completion

Sep 15, 2025

Study completion Sep 15, 2025

Sponsor

Lead sponsor
Silver Creek PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Oct 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy for Acute Ischemic Stroke

Conditions

  • Acute Ischemic Stroke (AIS)

Interventions

  • PlaceboDrug

    Volume Matched Placebo

  • scp776 (1.9 mg/kg)Drug

    Cohort 1 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes \- 1.9 mg/kg

  • scp776 (3.8 mg/kg)Drug

    Cohort 2 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes \- 3.8 mg/kg

  • scp776 (4.8 mg/kg)Drug

    Cohort 3 dose regimen: Intravenous (IV) slow injection(s) over 2 minutes - 4.8 mg/kg

  • scp776 (all dose levels)Drug

    A composite group encompassing all participants who received any dose level of the investigational drug under evaluation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Total number of SAEs recorded prior to hospital dischargeTime frame: Baseline to Day 7 or at hospital discharge (whichever occurs first).
  2. Proportion of subjects experiencing adverse events of special interest (AESIs)Time frame: Baseline to Day 7 or at hospital discharge (whichever occurs first).

Locations

22 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Scottsdale Osborn Medical Center

    Scottsdale, Arizona

  • Banner University Medical Center /Univ of Arizona

    Tucson, Arizona

  • Hartford Hospital

    Hartford, Connecticut

  • Marcus Neuroscience Institute

    Boca Raton, Florida

  • University of Miami - Jackson Memorial Hospital

    Miami, Florida

  • Augusta University Medical Center

    Augusta, Georgia

  • SSM Health DePaul Hospital

    Bridgeton, Missouri

  • St. Luke's Hospital of Kansas City

    Kansas City, Missouri

  • UNM Hospital

    Albuquerque, New Mexico

  • Northshore University Hospital

    Manhasset, New York

  • Lennox Hill Hospital

    New York, New York

  • University of Cincinnati

    Cincinnati, Ohio

  • The Ohio State University

    Columbus, Ohio

  • Mercy Health - St Vincent Medical Center

    Toledo, Ohio

  • Mercy Health - St Elizabeth Youngstown Hospital

    Youngstown, Ohio

  • Providence Portland Medical Center

    Portland, Oregon

  • Oregon Stroke Center at OHSU

    Portland, Oregon

  • Providence St. Vincent Medical Center

    West Haven-Sylvan, Oregon

  • Jefferson Abington Hospital

    Abington, Pennsylvania

  • Penn State Health - M.S. Hershey Medical Center

    Hershey, Pennsylvania

  • Houston Methodist Neurological Institute

    Houston, Texas

  • Medical College of Wisconsin and Froedtert Hospital

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.